Treatment for Stage 3 CKD is a serious health problem

Treatment for Stage 3 CKD

Treatment for Stage 3 CKD is a serious health problem, often associated with other common chronic diseases such as diabetes, hypertension, and cardiovascular disease (CVD)2 and an estimated 1:10 British Columbians has some form of significant kidney disease.3

Staging of CKD is now determined by the combined results of kidney function (eGFR) and the level of albuminuria.

There are many different types and causes of kidney disease. These can be characterized as hereditary, congenital or acquired.
Diabetes is the leading cause Treatment for Stage 3 CKD and is associated with excessive cardiovascular morbidity and mortality (1,2). Anemia is common among those with diabetes and Treatment for Stage 3 CKD and greatly contributes to patient outcomes (3,4). Observational studies indicate that low Hb levels in such patients may increase risk for progression of kidney disease and cardiovascular morbidity and mortality (5). Controlled clinical trials of anemia treatment with erythropoietin stimulating agents (ESAs) demonstrated improved quality of life (QOL) but have not demonstrated improved outcomes (6–10).
Treatment for Stage 3 CKD amplifies risk for multiple conditions: cardiac morbidity and mortality risk is elevated 10 times that of population mean risk;4,5 length of hospital stay and adverse reactions to drugs are also increased;6-10 and renal replacement therapy (RRT) is only one, rarer outcome.6,9,11-13 People with CKD also have higher risk of acute kidney injury (AKI).13,14 AKI in those with existing CKD is associated with high morbidity and mortality.15,16


Treatment for Stage 3 CKD usually affects both kidneys. If the kidneys' ability to remove and regulate water and chemicals is seriously damaged by disease, waste products and excess fluid build up occur, causing severe swelling and symptoms of uremia (kidney failure).

http://www.sjzkidneyhospital.com/tags.php?/CKD+Treatment/